Novartis

Novartis collaboration aims to eliminate rheumatic heart disease (RHD) in Zambia, Africa

NovartisNovartis today announced that it has launched an effort to eliminate rheumatic heart disease in Zambia in collaboration with the Lusaka University Teaching Hospital (UTH), the Ministry of Health in Zambia, the Pan-African Cardiology Society and Massachusetts General Hospital (MGH).

RHD is a complication of untreated streptococcal infections in which the valves of the heart are scarred and eventually degenerate, leading to heart failure. Eliminated by antibiotic treatment in most developed nations, in the developing world an estimated 15 million children suffer from this debilitating and often fatal disease.

"The toll of heart failure in young children with RHD in Zambia is immense, for the patient, their families, and the nation," said Mark C. Fishman, Cardiologist and President of the Novartis Institutes for BioMedical Research (NIBR). "It is entirely preventable. For the past several years Novartis has been working with colleagues in Lusaka to help understand and treat asthma in young children. We are expanding the collaboration to raise awareness, educate, and provide antibiotic therapy to prevent RHD."

To measure RHD prevalence and identify those in need of secondary prophylaxis, teams of health care professionals from Lusaka UTH, the MGH, and Novartis will use portable echocardiography machines to evaluate 3,000 children, ages 9-10, in Lusaka-area public schools. Echocardiography screening is estimated to detect more than 10 times as many cases as clinical screening.

Images from the echocardiography screens will be analyzed in Zambia and at the MGH using a cloud-based electronic registry developed by Dimagi Inc, a Cambridge, MA-based company that designs open-source electronic healthcare systems for low resource environments.

Children identified as having RHD will be treated with monthly penicillin injections (termed "secondary prophylaxis") to prevent recurrent streptococcal infections and additional valve damage.

Primary prevention, the treatment of children with streptococcal infection to prevent RHD, is key to elimination of the disease. To this end, all children diagnosed with strep throat will be treated with injectable penicillin in the community-based study sites. Prevalence of RHD and adherence to secondary prophylaxis will be determined via the mobile electronic registry.

"We have assembled an experienced team from MGH who are excited to bring the mobile heart imaging technology to Zambia," stated Michael H. Picard, MD, Director of Echocardiography at the Massachusetts General Hospital and a Past President of the American Society of Echocardiography. "We are creating a model for country-wide screening through schools that will not only raise awareness of the magnitude of this disease but also offer a simple method to identify those who will benefit from a very simple and safe treatment. The MGH Cardiology Division and its Cardiac Ultrasound Laboratory are delighted to be a partner in this initiative."

The Pan-African Cardiology Society will assist with the development of the study protocol and ethics approval. Based on the experience of the initial Lusaka-based effort, Novartis plans to support the rollout of the RHD training and treatment effort to Provinces across Zambia, with the ultimate goal of eliminating RHD in Zambia.

"Rheumatic heart disease is the most common acquired heart ailment in Zambian children, but statistics are spotty and the disease is certainly diagnosed late when damage to the heart valves has already reached advanced stage," said John Musuku, Principal Investigator and UTH pediatrician. "Our hope is that the collaboration with Novartis will lay the foundation to detect the disease early so preventative measures are instituted. This is an effort to eradicate the disease across Zambia in our life time."

About Novartis
The Novartis Institutes for BioMedical Research (NIBR) is the global pharmaceutical research organization for Novartis. NIBR's research network is comprised of more than 6,000 scientists, physicians and business professionals working together across more than ten locations to discover innovative medicines to treat diseases with high unmet medical need.

Headquartered in Cambridge, Massachusetts, USA, NIBR is an affiliate of Novartis AG, which provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2012, the Group achieved net sales of USD 56.7 billion, while R&D throughout the Group amounted to approximately USD 9.3 billion (USD 9.1 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 128,000 full-time-equivalent associates and operate in more than 140 countries around the world.

Most Popular Now

World's first public dengue immuniz…

Sanofi and its vaccines global business unit Sanofi Pasteur announced today that the first public dengue immunization program has started in the Philippines. At a major l...

Read more

NIH launches large clinical trials …

Enrollment has begun in the first of two multinational clinical trials of an intravenously delivered investigational antibody for preventing HIV infection. Known as the A...

Read more

AstraZeneca and Eli Lilly and Compa…

AstraZeneca and Eli Lilly and Company today announced that AMARANTH, a Phase II/III study of AZD3293, an oral beta secretase cleaving enzyme (BACE) inhibitor currently in...

Read more

Saxenda® demonstrated significant i…

Today, new data from the three-year part of the phase 3a SCALE™ (Satiety and Clinical Adiposity - Liraglutide Evidence) Obesity and Prediabetes trial were presented at th...

Read more

Vitamin D improves heart function, …

A daily dose of vitamin D3 improves heart function in people with chronic heart failure, a five-year University of Leeds research project has found. Dr Klaus Witte, from ...

Read more

Pfizer announces termination of pro…

Pfizer Inc. (NYSE: PFE) announced that the merger agreement between Pfizer and Allergan plc (NYSE: AGN) has been terminated by mutual agreement of the companies. The deci...

Read more

New analysis shows only minority of…

Boehringer Ingelheim has announced a new publication showing that levels of white blood cells called eosinophils can help identify patients with COPD who may and may not ...

Read more

Researchers open the way to new tre…

In a recent paper published in Nature Communications, a group of Case Western University School of Medicine researchers presented their discovery of the full-length struc...

Read more

Implantable device targets pancreat…

Pancreatic cancer is the third leading cause of cancer deaths in the United States, in part because it is very difficult for chemotherapy drugs to reach the pancreas, whi...

Read more

Physicians' knowledge about FDA app…

Since 2012, the FDA can designate a drug as a "breakthrough therapy" if preliminary clinical evidence - such as an improvement in a pharmacodynamic biomarker - suggests a...

Read more

Global spending on health is expect…

Global inequities in health spending are expected to persist and intensify over the next 25 years, according to a new study that estimates total health financing in count...

Read more

Americans live longer but with disa…

Americans are living longer but in poorer health, according to a new study. The USC-led study examined life expectancy trends and disability rates in a 40-year period, fr...

Read more

Digest World Pharma Newsletter

Subscribe to our weekly Digest World Pharma Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]